Lilly, ThyssenKrupp, Adidas, AMD: Intellectual Property

May 17 (Bloomberg) -- Canada’s Supreme Court dismissed Eli Lilly & Co.’s request to appeal a federal court decision that invalidated its Canadian patent for schizophrenia drug Zyprexa.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.